Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nexgel Inc (NXGL)

Nexgel Inc (NXGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,553
  • Shares Outstanding, K 8,143
  • Annual Sales, $ 8,690 K
  • Annual Income, $ -3,280 K
  • EBIT $ -3 M
  • EBITDA $ -3 M
  • 60-Month Beta 0.62
  • Price/Sales 0.45
  • Price/Cash Flow N/A
  • Price/Book 1.05
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.34
  • Most Recent Earnings $-0.08 on 11/11/25
  • Next Earnings Date 03/23/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Instruments

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6500 +3.89%
on 03/20/26
1.2500 -45.98%
on 02/27/26
-0.4347 (-39.16%)
since 02/25/26
3-Month
0.6500 +3.89%
on 03/20/26
1.9000 -64.46%
on 01/02/26
-0.9147 (-57.53%)
since 12/24/25
52-Week
0.6500 +3.89%
on 03/20/26
3.1900 -78.83%
on 03/26/25
-2.3547 (-77.71%)
since 03/25/25

Most Recent Stories

More News
NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 25, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”),...

NXGL : 0.6753 (-0.97%)
NXGLW : 0.0585 (-0.68%)
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio  ...

CELU : 1.2100 (-4.72%)
NXGL : 0.6753 (-0.97%)
NXGLW : 0.0585 (-0.68%)
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications. Three pipeline...

CELU : 1.2100 (-4.72%)
NXGL : 0.6753 (-0.97%)
CELUW : 0.0075 (-8.54%)
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified...

CELU : 1.2100 (-4.72%)
NXGL : 0.6753 (-0.97%)
NXGLW : 0.0585 (-0.68%)
NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence

LANGHORNE, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products...

NXGL : 0.6753 (-0.97%)
NXGLW : 0.0585 (-0.68%)
NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor

LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products...

NXGL : 0.6753 (-0.97%)
NXGLW : 0.0585 (-0.68%)
NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx

NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off NEXGEL will also receive a 5% global royalty in perpetuity on...

NXGL : 0.6753 (-0.97%)
NXGLW : 0.0585 (-0.68%)
NEXGEL Reports Third Quarter 2025 Financial Results

LANGHORNE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products...

NXGL : 0.6753 (-0.97%)
NXGLW : 0.0585 (-0.68%)
NEXGEL to Report Third Quarter 2025 Financial Results on November 11th

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”),...

NXGL : 0.6753 (-0.97%)
NXGLW : 0.0585 (-0.68%)
NEXGEL to Present at the LD Micro Main Event XIX Conference on October 19-21

LANGHORNE, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products...

NXGL : 0.6753 (-0.97%)
NXGLW : 0.0585 (-0.68%)

Business Summary

NexGel Inc. is a provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. The company developed and manufactured electron-beam, cross-linked hydrogels. NexGel Inc. is based in Langhorne, Pa.

See More

Key Turning Points

3rd Resistance Point 0.7759
2nd Resistance Point 0.7522
1st Resistance Point 0.7171
Last Price 0.6753
1st Support Level 0.6583
2nd Support Level 0.6346
3rd Support Level 0.5995

See More

52-Week High 3.1900
Fibonacci 61.8% 2.2197
Fibonacci 50% 1.9200
Fibonacci 38.2% 1.6203
Last Price 0.6753
52-Week Low 0.6500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.